PLASMAtech: PlasmaTech, Norgine sign license deal to commercialize MuGard in Australia and New Zealand
PlasmaTech Biopharmaceuticals has entered into an exclusive license agreement with European pharmaceutical firm Norgine to commercialize MuGard, an oral mucoadhesive, in Australia and New Zealand.
Read full article »
CEO
PLASMAtech designs, markets, and sells illuminated signboard products.
Read more